Terms: = Liver cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
13 results:
1.
Lu J; Ding Y; Zhang W; Qi Y; Zhou J; Xu N; Zhang Y; Xie W
Cells; 2023 Apr; 12(9):. PubMed ID: 37174639
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathologic features of gastric glomus tumor: A report of 15 cases and literature review.
Deng M; Luo R; Huang J; Luo Y; Song Q; Liang H; Xu C; Yuan W; Hou Y
Pathol Oncol Res; 2022; 28():1610824. PubMed ID: 36699621
[No Abstract] [Full Text] [Related]
3. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract] [Full Text] [Related]
4. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Mechanisms of Hepatoblastoma.
Zhang Y; Solinas A; Cairo S; Evert M; Chen X; Calvisi DF
Semin Liver Dis; 2021 Jan; 41(1):28-41. PubMed ID: 33764483
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-keap1 Controls the Fate of Hepatocarcinogenesis.
Haque E; Karim MR; Salam Teeli A; Ĺmiech M; Leszczynski P; Winiarczyk D; Parvanov ED; Atanasov AG; Taniguchi H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751080
[TBL] [Abstract] [Full Text] [Related]
7. Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model.
Kunimasa K; Hirotsu Y; Nakamura H; Tamiya M; Iijima Y; Ishida H; Hamamoto Y; Maniwa T; Kimura T; Nishino K; Goto T; Amemiya K; Mochizuki H; Oyama T; Nakatsuka SI; Kumagai T; Okami J; Higashiyama M; Imamura F; Omata M
Cancer Genet; 2020 Feb; 241():51-56. PubMed ID: 31917104
[TBL] [Abstract] [Full Text] [Related]
8. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the keap1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract] [Full Text] [Related]
9. RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for keap1 Binding.
Wan ZH; Jiang TY; Shi YY; Pan YF; Lin YK; Ma YH; Yang C; Feng XF; Huang LF; Kong XN; Ding ZW; Tan YX; Dong LW; Wang HY
Hepatology; 2020 Jun; 71(6):2005-2022. PubMed ID: 31541481
[TBL] [Abstract] [Full Text] [Related]
10. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.
Gao Q; Zhang G; Zheng Y; Yang Y; Chen C; Xia J; Liang L; Lei C; Hu Y; Cai X; Zhang W; Tang H; Chen Y; Huang A; Wang K; Tang N
Cell Death Differ; 2020 Mar; 27(3):1086-1104. PubMed ID: 31367013
[TBL] [Abstract] [Full Text] [Related]
11. The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62.
Xu D; Li X; Shao F; Lv G; Lv H; Lee JH; Qian X; Wang Z; Xia Y; Du L; Zheng Y; Wang H; Lyu J; Lu Z
Sci Adv; 2019 Apr; 5(4):eaav4570. PubMed ID: 31032410
[TBL] [Abstract] [Full Text] [Related]
12. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract] [Full Text] [Related]
13. Clinical implication of keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.
Chen J; Yu Y; Ji T; Ma R; Chen M; Li G; Li F; Ding Q; Kang Q; Huang D; Liang X; Lin H; Cai X
Cancer Med; 2016 Oct; 5(10):2678-2687. PubMed ID: 27650414
[TBL] [Abstract] [Full Text] [Related]
